ERBB2 and cancer: In our cohort, MCL1 amplification was predictive of inferior OS, likely related to the resistance to endocrine, cytotoxic and anti-HER2 therapies reported in preclinical studies.20,21 The in vitro activity of MCL1 inhibitors alone or in combination with other anti-cancer drugs provide a strong rationale for their clinical development.22,23